香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 二零二五年第一季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其附 屬公司統稱「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」） 第13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下 的內幕消息條文（定義見上市規則）而作出。 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年四月二十三日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及李家聰先生組成。 茲載列本公司在深圳證 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was approximately RMB 5,804.66 million, a decrease of 25.40% compared to RMB 7,781.44 million for the year ended December 31, 2023[16]. - The gross profit margin for the reporting period was approximately 41.03%, down 9.86 percentage points from 50.89% in the same period last year[17]. - The net profit attributable to shareholders of the parent company was approximately RMB 948.95 million, a decline of 58.17% from RMB 2,268.81 million in the previous year[18]. - In Q4 2024, the company's operating revenue increased by 15.83% year-on-year and 19.37% quarter-on-quarter, with net profit attributable to shareholders at RMB 238.62 million, a 12.99% increase quarter-on-quarter[25]. - The net profit attributable to shareholders for the reporting period was RMB 948.95 million, a decrease of 58.17% year-on-year, primarily due to the absence of high-margin large orders from the previous year and low gross margins in emerging businesses[25]. - The adjusted net profit attributable to shareholders was RMB 803.07 million, a 65.12% decrease compared to 2023[75]. - The net profit decreased by 58.43% from RMB 2,250.82 million in 2023 to RMB 935.76 million in 2024, with a net profit margin of 16.35%, down 12.81 percentage points from 29.16% in 2023[93]. - Basic and diluted earnings per share fell from RMB 6.26 in 2023 to RMB 2.69 in 2024, primarily due to the decline in net profit[94]. Business Growth and Development - In 2024, Asymchem Laboratories achieved an 8.28% year-on-year growth after excluding the impact of large orders during the pandemic, maintaining strong profitability in its small molecule CDMO business[8]. - The company is expanding its emerging business in peptide, antibody-drug conjugates (ADC), and oligonucleotide markets, with a notable increase in project deliveries and orders in the fourth quarter[8]. - The company signed new orders in 2024, with a year-on-year growth of approximately 20%, particularly from European and American markets, which exceeded the overall order growth rate[23]. - The emerging business segment generated revenue of RMB 1,226.37 million, an increase of 4.80% year-on-year, with overseas customer revenue growing by 15.41%[24]. - The biopharmaceutical CDMO segment revenue increased by 17.36% year-on-year, with over 60 ongoing orders, including IND and multiple BLA stage projects, and a 56% increase in orders year-on-year[40]. - The chemical macromolecule CDMO business, including peptides, saw a revenue growth of 15.66% year-on-year, with over 200% quarter-on-quarter growth in Q4 2024 and more than 130% year-on-year increase in backlog orders[37]. - The company is focusing on strategic reserves of potential blockbuster projects, particularly in the GLP-1 weight loss area, with 12 projects expected to reach the PPQ stage by 2025[34]. Research and Development - The company has automated peptide synthesis and purification capabilities, with solid-phase synthesis capacity exceeding 20,000 liters, and plans to further increase production scale[9]. - Continuous investment in research and development for continuous reaction technology is driving market demand and recognition for continuous processes[10]. - Research and development expenses for the year ending December 31, 2024, amounted to RMB 614.49 million, representing 10.59% of total revenue, with plans for continued proportional investment in R&D[48]. - The company aims to increase R&D investment to strengthen its research platform and promote smart manufacturing technologies[139]. - The company has published a total of 47 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[48]. Operational Efficiency and Technology - Asymchem's advanced manufacturing technologies, including continuous flow reaction and synthetic biology, are gaining traction globally, enhancing the company's competitive edge in the pharmaceutical and fine chemical industries[10]. - The company is focusing on enhancing its green chemistry capabilities to reduce costs and improve efficiency in pharmaceutical process development[7]. - The company is committed to seamless integration of cutting-edge technologies and industrial applications to strengthen its competitive edge in the CDMO industry[44]. - The company is one of the few able to apply continuous production technology at a ton-scale level, creating a strong competitive advantage by simplifying process paths and reducing raw material costs[47]. - The fixed enzyme continuous reaction technology has been successfully applied in the production of multiple ton-level products, achieving production capacity increases of up to 1,500 times compared to traditional enzyme catalysis[50]. Market Position and Customer Relationships - The company has established partnerships with 16 out of the top 20 global pharmaceutical companies, with 8 of these relationships lasting over a decade, indicating strong customer loyalty and retention[126]. - The company aims to enhance its CDMO products and services, expanding into advanced drug categories including peptides, oligonucleotides, monoclonal antibodies, and ADCs[122]. - The company is actively expanding its global customer base by deepening relationships with existing clients and targeting small to medium-sized innovative drug companies[131]. - The company aims to strengthen relationships with key customers and actively seek growth opportunities in domestic and international markets[23]. Sustainability and Corporate Responsibility - The company is committed to sustainable development and social responsibility, actively engaging with stakeholders to create a harmonious business environment[71]. - The company has established a comprehensive ESG management system and supply chain behavior guidelines to meet the expectations of overseas clients[72]. - The company has implemented environmental policies and measures, promoting energy conservation and waste reduction among employees[180]. - The company is committed to green operations and actively practices environmental sustainability[180]. Human Resources and Management - The company has introduced 245 senior talents in 2024, including 78 PhDs and 136 individuals with overseas pharmaceutical experience[69]. - The total number of employees reached 9,595 by December 31, 2024, with approximately 78% holding a bachelor's degree or higher[69]. - The company emphasizes talent management strategies to attract and retain diverse professionals in the competitive pharmaceutical industry[68]. - The company has a stable and experienced senior management team, with many members having over 20 years of industry experience, ensuring strong governance and operational effectiveness[128]. Future Outlook and Strategic Plans - The company plans to continue enhancing its global supply chain through multi-site production capacity to support global partners in accelerating drug launches[13]. - In 2025, the company plans to accelerate overseas expansion by establishing production capabilities in Europe and enhancing collaboration with international pharmaceutical companies[136]. - The company intends to enrich its service offerings and expand overseas by seeking investments for strategic capacity expansion and enhancing collaboration with multinational companies[133]. - The company aims to rebalance profitability by improving the gross margin of its core small molecule CDMO business and controlling costs in emerging businesses[137].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 截至2024年12月31日止年度之年度業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」或「凱萊英」，連同其附屬公司， 統稱「本集團」）董事（「董事」）會（「董事會」）欣然公佈本集團截至2024年12月31 日止年度（「報告期」）的經審計綜合年度業績，連同截至2023年12月31日止年度 （「同期」）之比較數字。本集團於報告期間的綜合財務報表已由董事會及審核委員 會審閱及由本公司核數師審核。 於本公告中，「我們」指本公司，如文義另有所指，指本集團。本公告所載若干金 額及百分比數字已作四捨五入調整，或約整至小數點後一位或兩位（如適用）。任 何表格、圖表或其他地方所列總數與數額總和如有任何差異，皆因約整所致。除 非本公告另有說明，否則本公告 ...

Financial Performance - Total revenue for the first half of 2024 was RMB 2,655.05 million, a decrease of 42.23% compared to RMB 4,595.71 million in the same period of 2023[12]. - Gross profit for the first half of 2024 was RMB 1,094.70 million, down 54.89% from RMB 2,426.69 million year-on-year[12]. - Net profit attributable to shareholders for the first half of 2024 was RMB 499.13 million, a decline of 70.40% compared to RMB 1,686.37 million in the previous year[12]. - The company reported a gross margin of 41.23% for the first half of 2024, which is a decrease of 11.57 percentage points from 52.80% in the same period last year[12]. - The adjusted net profit attributable to shareholders was RMB 432.72 million, reflecting a 73.56% decrease from RMB 1,636.43 million year-on-year[12]. - The company's revenue for the reporting period was RMB 1,282.25 million, a decrease of 58.59% year-on-year, but a 10.29% increase when excluding the impact of large orders[17]. - Revenue from small and medium-sized companies in the first half of 2024 was RMB 1,372.80 million, down 8.44% year-on-year, with over 1,100 active global customers served[17]. - Overseas business revenue for the company was RMB 1,965.94 million, a decrease of 48.72% year-on-year, but a 3.45% increase when excluding large orders[17]. - Revenue from U.S. customers was RMB 1,741.52 million, showing a significant year-on-year growth of 24.78% when excluding large orders[18]. - The company confirmed revenue from 310 clinical stage projects, generating RMB 787.69 million, a decrease of 7.82% year-on-year[40]. - The company reported total comprehensive income of RMB 498,891 thousand for the six months ended June 30, 2024, compared to RMB 1,693,831 thousand in 2023, reflecting a decrease of 70.6%[166]. Revenue Breakdown - Revenue from small molecule CDMO services was RMB 2,153.42 million, showing a slight increase of 1.09% year-on-year after excluding large orders[14]. - Revenue from emerging business segments was RMB 499.62 million, down 5.30% year-on-year due to a lack of recovery in domestic biopharmaceutical financing[14]. - Revenue from commercialized CDMO solutions was RMB 1,365.73 million, a decline of 57.44% year-on-year, but a growth of 7.06% after excluding large orders[39]. - Revenue from clinical and preclinical CDMO solutions was RMB 787,694,000, a decrease of 7.8% from RMB 854,544,000 in the previous year[186]. - Revenue from commercial stage CDMO solutions was RMB 1,365,725,000, down 57.5% from RMB 3,209,311,000 in the same period last year[186]. - Revenue from emerging businesses was RMB 499,615,000, a slight decrease of 5.3% from RMB 527,592,000 in the previous year[186]. Operational Highlights - The company added 114 new customers during the reporting period, highlighting its operational strength and solid global customer base[14]. - The company aims to further expand its scale despite the termination of large orders, indicating a commitment to growth[14]. - The company is focusing on expanding its customer base and enhancing service depth, particularly in the U.S., Europe, and China markets[24]. - The company anticipates 28 projects to reach the verification batch stage in the second half of 2024, providing strong support for long-term growth[23]. - The company has established partnerships with 16 out of the top 20 global pharmaceutical companies, with 8 of these relationships lasting over 10 years, indicating strong customer loyalty and retention[77]. Research and Development - The company invested RMB 328.69 million in R&D during the first half of 2024, an increase of 1.61% year-on-year, representing 12.38% of total revenue[38]. - Research and development expenses for the period were RMB 328,688 thousand, slightly up from RMB 323,471 thousand in 2023, indicating a focus on innovation despite overall revenue decline[165]. - The company has introduced a tailored talent strategy for each major business segment, hiring 60 senior talents in the first half of 2024, including 33 PhDs[35]. - The company is committed to continuous innovation and has developed internationally recognized patented technologies that are now applied in commercial manufacturing[81]. - The company aims to increase R&D investment to strengthen its research platform and promote smart manufacturing technologies[90]. Financial Position - Cash and bank balances decreased by RMB 1,431.06 million or 20.13% compared to June 30, 2023, primarily due to share repurchases[56]. - The company had no bank borrowings as of June 30, 2024, compared to RMB 12.23 million as of December 31, 2023[56]. - As of June 30, 2024, the company's current assets include inventory of RMB 997,959 thousand, an increase of 5.57% from RMB 945,347 thousand as of December 31, 2023, primarily due to fluctuations from continuous order deliveries[57]. - Trade receivables decreased by 26.23% to RMB 1,483,415 thousand from RMB 2,010,989 thousand, mainly due to the collection of accounts receivable[57]. - The company's total liabilities to total assets ratio increased to 12.76% as of June 30, 2024, from 11.42% as of December 31, 2023[66]. Corporate Governance - The company has complied with the corporate governance code and has not identified any violations by employees during the reporting period[153]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[155]. - The board believes that having the same person serve as both Chairman and CEO will enhance the effective execution of strategic initiatives and improve communication between management and the board[154]. - The company has not faced any investigations or administrative penalties from the China Securities Regulatory Commission during the reporting period[156]. - The company will continue to review and assess the effectiveness of its corporate governance framework[154]. Future Outlook - The company aims to enhance its CDMO services by incorporating advanced drug categories, including peptides, oligonucleotides, and mRNA[76]. - The company is committed to becoming a reliable partner in the global pharmaceutical industry, providing comprehensive CDMO services throughout the drug development lifecycle[76]. - The company plans to enhance its talent acquisition and retention strategies to ensure consistent high-quality service delivery, including tailored training programs and competitive compensation[86]. - The company is currently assessing the impact of the second pillar income tax legislation on its future financial performance, indicating a proactive approach to regulatory changes[190]. - The company plans to utilize the raised funds for various projects, with specific timelines for completion ranging from 2025 to 2026[136][137][138][139].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或倚賴該 等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至二零二四年六月三十日止六個月 中期業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公佈本公司及其附屬公司（統稱「本集團」、「我們」）截至 二零二四年六月三十日止六個月（「報告期」）的未經審計綜合中期業績，連同截至 二零二三年六月三十日止六個月（「同期」）之比較數字。本集團於報告期間的綜合 財務報表已由董事會及審核委員會審閱及由本公司核數師審核。 於本公告中，金額及百分比數字已作四捨五入調整，或約整至小數點後一位或兩 位（如適用）。任何表格、圖表或其他地方所列總數與數額總和如有任何差異，皆 因約整所致。除非本公告另有說明，否則本公告所用詞彙與本公司日期 ...

Financial Performance - The company reported total revenue of RMB 1,399,808,311.93 for Q1 2024, a decrease of 37.76% compared to RMB 2,249,034,497.62 in the same period last year[10]. - Net profit attributable to shareholders was RMB 281,970,252.06, down 55.27% from RMB 630,346,004.43 year-on-year[10]. - The net profit after deducting non-recurring items was RMB 253,974,228.11, reflecting a 58.88% decline compared to RMB 617,637,901.61 in the previous year[10]. - Basic and diluted earnings per share were both RMB 0.76, down 55.81% from RMB 1.72 in the same period last year[10]. - Total revenue for Q1 2024 was approximately ¥1.40 billion, a decrease of 37.76% compared to ¥2.25 billion in Q1 2023, primarily due to the impact of large orders in the same period last year[18]. - Operating profit decreased to RMB 294.69 million, a decline of 58.5% compared to RMB 709.95 million in the prior period[38]. - Net profit for the reporting period was RMB 279.53 million, down 55.5% from RMB 627.89 million in the previous period[40]. - Total revenue for the reporting period was RMB 1.40 billion, down 37.8% from RMB 2.25 billion in the previous period[38]. - The company reported a net loss attributable to the parent company of RMB 281,971,000 in Q1 2024, compared to a profit of RMB 630,346,000 in Q1 2023[47]. Revenue Breakdown - Revenue from small molecule business reached RMB 1,223,000,000, with a year-on-year growth of 26.58% after excluding last year's large order impact[13]. - Revenue from emerging businesses was RMB 176,000,000, down 29.30% year-on-year due to the ongoing impact of the domestic investment environment[13]. - Cash received from sales of goods and services was approximately ¥1.74 billion, down 36.76% from ¥2.76 billion in the previous year, influenced by large order repayments from last year[18]. Costs and Expenses - Total costs for Q1 2024 were approximately ¥1.14 billion, down 27.27% from ¥1.57 billion in Q1 2023, mainly due to the decline in revenue[18]. - Sales expenses increased by 31.95% to approximately ¥44.62 million, reflecting continued investment in market expansion and sales activities[18]. - The company reported a significant increase in tax and additional charges, which rose by 374.77% to approximately ¥41 million, attributed to export tax rebates[18]. - Research and development expenses for the period were RMB 169.44 million, an increase from RMB 162.10 million in the previous period[38]. - Research and development expenses for Q1 2024 were RMB 169,442,000, slightly higher than RMB 162,097,000 in Q1 2023[47]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 19,841,423,232.54, a slight increase of 0.38% from RMB 19,767,158,652.70 at the end of the previous year[10]. - Total current assets decreased to RMB 12.11 billion from RMB 12.35 billion, primarily due to a reduction in trading financial assets[31]. - The company reported a total liability of RMB 2.23 billion, slightly down from RMB 2.26 billion at the beginning of the period[35]. - The company’s total equity as of March 31, 2024, was RMB 17,606,958,000, an increase from RMB 17,509,979,000 at the end of the previous year[55]. Cash Flow and Investments - Net cash flow from operating activities for the reporting period was RMB 490,666,474.36, significantly lower than RMB 1,303,525,263.66 in the previous period[44]. - Cash and cash equivalents at the end of Q1 2024 totaled RMB 4,774,669,819.21, down from RMB 5,379,198,112.41 at the end of the previous year[45]. - The cash flow from investing activities showed a net outflow of RMB 284,603,126.59, compared to a net outflow of RMB 327,218,213.85 in the previous period[44]. - The company experienced a foreign exchange gain of RMB 15,685,123.62 during the reporting period, contrasting with a loss of RMB 15,286,791.15 in the previous period[45]. - The company experienced a net cash outflow from investing activities of RMB 284,603 thousand in Q1 2024, compared to RMB 327,218 thousand in Q1 2023[59]. Share Repurchase and Capital Management - The company repurchased shares, resulting in cash payments of approximately ¥218.69 million, marking a new strategy in capital management[18]. - The company plans to repurchase shares with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a repurchase price not exceeding RMB 157 per share[29]. - The financing activities resulted in a net cash outflow of RMB 218,690 thousand in Q1 2024, with share repurchase payments amounting to RMB 213,367 thousand[59]. Project Development - The company confirmed 30 small molecule commercialization projects and 148 clinical stage projects, including 41 in Phase III[13].

Asymchem Laboratories (Tianjin) Co., Ltd. 凱 萊 英 醫 藥 集 團（ 天 津 ）股 份 有 限 公 司 ( 於中華人民共和國註冊成立的股份有限公司 ) www.asymchem.com 股份代號 : 6821 2023 年度報告 - Casymchem j : 目錄 公司資料 | --- | --- | |----------------------------|-------| | | | | | 2 | | 董事長報告 | 4 | | 財務摘要 | 8 | | 管理層討論與分析 | 10 | | 董事、監事及高級管理層履歷 | 52 | | 董事會報告 | 62 | | 企業管治報告 | 87 | | 獨立核數師報告 | 115 | | 綜合損益表 | 121 | | 綜合全面收益表 | 122 | | 綜合財務狀況表 | 123 | | 綜合權益變動表 | 125 | | 綜合現金流量表 | 127 | | 財務報表附註 | 129 | | 釋義 | 211 | 公司資料 | --- | --- | --- | --- | |-------|--------- ...

Financial Performance - Total revenue for 2023 was RMB 7,781.44 million, a decrease of 23.94% compared to RMB 10,230.19 million in 2022[6] - Gross profit for 2023 was RMB 3,959.64 million, down 18.06% from RMB 4,832.59 million in 2022, with a gross margin of 50.89%, an increase of 3.65% year-on-year[6] - Net profit attributable to shareholders for 2023 was RMB 2,268.81 million, a decline of 31.28% from RMB 3,301.64 million in 2022, resulting in a net profit margin of 29.16%[6] - Adjusted net profit attributable to shareholders was RMB 2,302.09 million, down 23.23% from RMB 2,998.81 million in 2022, with an adjusted net profit margin of 29.58%[6] - The company confirmed 40 commercial projects generating revenue of RMB 5,107.49 million, a decline of 32.51% year-on-year[78] - Net profit decreased by 31.68% from RMB 3,294.63 million in 2022 to RMB 2,250.82 million in 2023, with a net profit margin of 29.16% compared to 32.27% in 2022[94] - Basic and diluted earnings per share fell from RMB 9.00 in 2022 to RMB 6.26 in 2023, reflecting the decline in net profit[95] Revenue Breakdown - Revenue from small molecule CDMO services was RMB 6,605.14 million, with remaining revenue (excluding large orders) of RMB 4,184.62 million, reflecting a year-on-year growth of 25.47%[11] - Revenue from multinational pharmaceutical companies was RMB 4,988.48 million, a decrease of 32.20%, but excluding large orders, revenue increased by 75.56% to RMB 2,567.96 million[12] - Revenue from U.S. customers was RMB 2,846.75 million, showing a significant year-on-year increase of 47.84%[15] - Emerging business segment revenue reached RMB 1,170.20 million, representing a year-on-year growth of 17.79%[11] - Revenue from overseas markets was RMB 6,344.16 million, a decrease of 26.83% year-on-year, but grew by 41.41% after excluding large orders[81] R&D and Innovation - Research and development expenditure exceeded RMB 707.86 million, accounting for 9.10% of total revenue[53] - The company has developed over 2,700 existing engineered enzymes, with more than 1,100 proprietary enzymes, and successfully developed 17 types of enzyme reagent kits for rapid screening[41] - The company has published 41 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[52] - The launch of the Biological Science Technology Center (CBTI) in May 2023 aims to enhance internal R&D capabilities and streamline process development[140] - The company plans to increase R&D investment and establish an iterative development platform to enhance process synthesis design and optimization[153] Market Position and Strategy - The company has established partnerships with 16 of the top 20 multinational pharmaceutical companies, with 8 of these relationships exceeding 10 years[25] - The company aims to deepen service offerings and expand its client base, particularly in the Japanese market, which has shown significant growth in 2023[27] - The company is focusing on enhancing clinical project reserves to ensure long-term growth, with a strategic emphasis on potential blockbuster projects in the clinical III phase[24] - The company aims to leverage its advanced R&D platforms and strong production capabilities to further enhance its market leadership in the small molecule CDMO sector[137] - The company is actively diversifying into areas such as macromolecular drugs, drug formulation services, and clinical research services, which are expected to open new growth avenues[145] Operational Efficiency - The company is actively optimizing the process development cycle to enhance delivery quality and efficiency, with multiple patents currently under application[49] - The company aims to enhance delivery capabilities and expand overseas markets by accelerating the development of emerging services, focusing on small nucleic acids, peptides, and ADC commercialization production capacity[152] - The company is focusing on creating potential technological advantages through the development of an AI protein design platform[43] - The company has expanded its lipid nanoparticle technology platform and is continuously developing various complex formulation technology platforms, including nasal sprays and aerosol inhalation solutions[36] - The company is committed to balancing economic benefits with social and environmental responsibilities, ensuring a transparent governance structure[72] Corporate Governance - The company has adopted corporate governance principles and believes it has complied with all except one guideline during the reporting period[162] - The roles of the chairman and CEO are held by the same individual, which the board believes does not compromise the balance of power within the company[163] - The board emphasizes high standards of corporate governance to protect shareholder interests and enhance corporate value[164] - The company has confirmed compliance with the standard code for securities trading throughout the fiscal year ending December 31, 2023[166] - The board proposed a final dividend of RMB 18.00 per 10 shares for the year ending December 31, 2023, totaling approximately RMB 664,080,355.80 (including tax), compared to RMB 656,437,642.20 in 2022[176]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821) 二零二三年第三季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其 附屬公司「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文（定義見上市規則）而作出。 茲載列本公司在深圳證券交易所網站刊發的《凱萊英醫藥集團（天津）股份有限公 司二零二三年第三季度報告》，僅供參閱。本公司二零二三年第三季度報告（「二 零二三年第三季度報告」）以中、英文雙語編製。如兩個版本有任何不相符之處， 應以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者，本公告所載 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 4,595,708, a decrease of 8.71% compared to RMB 5,034,065 for the same period in 2022[18]. - Net profit attributable to shareholders was RMB 1,686,368, a decrease of 3.09% from RMB 1,740,095 in the prior year, with a net profit margin of 36.7%[18]. - Basic earnings per share for the first half of 2023 were RMB 4.65, down from RMB 4.75 in the previous year[18]. - The total revenue for the reporting period reached RMB 4.596 billion, with a year-on-year growth of 32.71% after excluding large orders[22]. - The company confirmed revenue from 34 commercial projects totaling RMB 3.209 billion, with a year-on-year growth of 60.50% after excluding large orders[28]. - The net profit for the first half of 2023 was RMB 1,686,368 thousand, compared to RMB 1,740,095 thousand in the same period of 2022, indicating a decrease of about 3.09%[179]. - Revenue from a single major customer for the six months ended June 30, 2023, was approximately RMB 2,225,728,303, down from RMB 3,212,304,000 for the same period in 2022, indicating a decrease of about 30.73%[192]. Profitability and Margins - Gross profit increased to RMB 2,426,685, representing a gross margin of 52.8%, up from 46.9% in the previous year[18]. - Adjusted net profit attributable to shareholders rose to RMB 1,636,426, reflecting a 6.44% increase from RMB 1,537,478 in the previous year[18]. - The overall gross margin increased by 6 percentage points to 52.85%, driven by improved margins on commercial projects and effective cost management[64]. - The adjusted net profit attributable to shareholders for the same period was RMB 1,636,426 thousand, compared to RMB 1,537,478 thousand in 2022, resulting in an adjusted net profit margin of 35.61%, up from 30.54%[85]. Revenue Breakdown - Revenue from small molecule CDMO business was RMB 4.064 billion, with a year-on-year growth of 32.41% after excluding large orders[22]. - Emerging business revenue reached RMB 528 million, showing a year-on-year increase of 34.33%[22]. - Revenue from US market customers was RMB 3.329 billion, with a year-on-year growth of 44.17% after excluding large orders[23]. - Revenue from clinical and pre-clinical CDMO solutions was RMB 854,544,000 for the first half of 2023, down from RMB 966,407,000 in 2022, reflecting a decrease of approximately 11.56%[197]. - Revenue from commercial stage CDMO solutions was RMB 3,209,311,000, a decrease of 12.59% from RMB 3,670,602,000 in the previous year[197]. Research and Development - The company invested RMB 323 million in R&D during the first half of 2023, representing a year-on-year increase of 22.84%[42]. - Research and development expenses rose by 23% to RMB 323.5 million, reflecting the company's commitment to technological innovation and core technology development[69]. - The company is committed to strengthening its R&D platform, utilizing iterative computing capabilities to support cross-departmental collaboration in process, engineering, and equipment[104]. Market and Business Strategy - The company is actively exploring new business areas, including chemical macromolecule CDMO and clinical CRO services[21]. - The company aims to expand its market influence by enhancing collaboration with multinational pharmaceutical companies and increasing penetration in the Japanese market[100]. - The business plan for 2023 focuses on deepening relationships with large clients, exploring small and medium-sized clients, and expanding into European and Japanese markets[99]. - The company is committed to a technology-driven strategy, emphasizing the continuous growth of its core small molecule CDMO business while developing strategic emerging industries[99]. Operational Efficiency - The company aims to optimize production processes continuously to reduce costs and improve efficiency, ensuring stable product quality and supply[20]. - The company has developed a modular solution for automated control of temperature, pressure, and pH, significantly improving production efficiency[45]. - The company is focused on integrating digital platforms and predictive capabilities to optimize production processes and enhance operational efficiency[43]. Financial Position - Cash and bank balances increased by RMB 1,752 million, a growth of 33%, mainly due to net cash inflow from operating activities of RMB 2,253 million[73]. - The asset-liability ratio decreased from 13.9% at the end of 2022 to 12.5% by June 30, 2023[78]. - Total assets increased by 4% to RMB 5,039,078 thousand, primarily due to the conversion of construction in progress[80]. - The company's total equity reached RMB 16,791,971 thousand, an increase from RMB 15,695,003 thousand as of December 31, 2022, representing a growth of approximately 6.96%[177]. Risks and Challenges - The company acknowledges potential risks related to the market exit or recall of major innovative drugs, emphasizing the need for proactive risk management[108]. - The company is aware of the uncertainties in the commercialization prospects of its clients' drugs, which may lead to lower-than-expected sales[109]. - The company faces risks related to international trade tensions and has planned effective backup measures to mitigate potential adverse effects[113]. Employee and Governance - The company introduced 73 senior talents during the reporting period, including 32 PhDs and 31 individuals with overseas pharmaceutical experience[49]. - The company emphasizes a "people-oriented" approach, focusing on employee rights and welfare, and has implemented stock incentive plans to boost employee motivation[53]. - The group had 9,145 employees as of June 30, 2023, with competitive compensation packages based on performance and market rates[157]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ending June 30, 2023[124]. - The company has granted a total of 3,327,450 restricted A shares under the A-share equity incentive plan as of June 30, 2023, representing approximately 0.90% of the total issued shares[143].